Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
Moonwalk Biosciences says new financing of $70 million will support an siRNA pipeline targeting adipose tissue and its discovery platform. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
The partners are exploring Avenue Biosciences' signal-peptide engineering with Circio's circVec technology to increase protein expression. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The companies announced joint development work spanning muscle disease gene therapy and in vivo cell-therapy applications. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reviews the translation of nonviral gene-delivery platforms, including lipid and polymer-based approaches. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports an amino-acid formulation approach intended to improve LNP delivery for mRNA and CRISPR cargo. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Their collaboration covers RNA-interference medicines and includes upfront funding and potential development-linked payments. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →SMRTS is a “smart” mRNA system that switches therapeutic genes on or off depending on cell type, enabling targeted cancer treatments while expanding the mRNA toolbox for precision medicine applications. The post Engineered mRNA System Delivers SMRTS for Cell-Selective Gene Expression appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The companies announced a gene-editing collaboration targeting rare liver diseases, marking Chiesi's entry into gene-editing development. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A two-step microfluidics system created ternary nano-scale lipopolyplexes, using polymer choice to determine the lipopolyplexes’ structure, which affects vector size and distribution. This overcomes barriers to manufacturing and creates nonviral vectors for efficient DNA delivery. The post Microfluidics-Manufactured Lipopolyplexes Offer Size Consistency appeared first on GEN - Genetic Engineering The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Engineered extracellular vesicles that deliver full-length DMD mRNA to skeletal muscle restored dystrophin production and significantly improved muscle strength and function in Duchenne muscular dystrophy models without notable toxicity. The post New mRNA Delivery Platform Restores Muscle Function in DMD Models appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call
